Cargando…

1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country

BACKGROUND: Tuberculosis (TB) is an infection caused by reactivation of Mycobacterium tuberculosis. Decreasing host immune system plays an important role in pathophysiology especially in patients with human immunodeficiency virus (HIV) infection and transplant recipients. Exposure to immunosuppressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Buppanharun, Jirawat, Vanichanan, Jakapat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808654/
http://dx.doi.org/10.1093/ofid/ofz360.1242
_version_ 1783461787695316992
author Buppanharun, Jirawat
Vanichanan, Jakapat
author_facet Buppanharun, Jirawat
Vanichanan, Jakapat
author_sort Buppanharun, Jirawat
collection PubMed
description BACKGROUND: Tuberculosis (TB) is an infection caused by reactivation of Mycobacterium tuberculosis. Decreasing host immune system plays an important role in pathophysiology especially in patients with human immunodeficiency virus (HIV) infection and transplant recipients. Exposure to immunosuppressive agents among patients with solid and hematologic malignancy is likely to increase risk of TB. However, characteristics of TB in this population remain scarce. METHODS: A single-center, retrospective descriptive study was conducted at King Chulalongkorn Memorial Hospital. Adult patients who developed TB between January 2008 and October 2018 after diagnosis of solid or hematologic malignancy were identified using ICD-10 code. Baseline, clinical characteristics, and treatment outcomes were collected. RESULTS: A total of 114 patients developed TB after diagnosis of malignancy including, 67 (58.8%) with solid tumor and 47 (41.2%) with hematologic malignancy. Lung cancer was the most common solid malignancy with TB (17.9%) followed by head and neck carcinoma (14.9%) and colorectal cancer (13.4%). For hematologic malignancies, non-Hodgkin’s lymphoma was the most common malignancy (53.2%) followed by leukemia (29.8%) and multiple myeloma (14.9%). Among patients who received immunosuppressive treatment, the mean onset of TB was 4.97 months (range 0.25 to 57 months) and 2.55 months (range 0.1 to 18 months) after treatment of solid and hematologic malignancies. Pulmonary and pleural involvement remained the most common site of infection in both groups. Mortality was highest among patients with hematologic malignancies (40.4%) while mortality in solid malignancies was 11.9%. CONCLUSION: TB in patients with solid and hematologic malignancies contained substantial morbidity and mortality. Immunosuppressive agents and chemotherapy may play an important role especially in the endemic area. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6808654
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68086542019-10-28 1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country Buppanharun, Jirawat Vanichanan, Jakapat Open Forum Infect Dis Abstracts BACKGROUND: Tuberculosis (TB) is an infection caused by reactivation of Mycobacterium tuberculosis. Decreasing host immune system plays an important role in pathophysiology especially in patients with human immunodeficiency virus (HIV) infection and transplant recipients. Exposure to immunosuppressive agents among patients with solid and hematologic malignancy is likely to increase risk of TB. However, characteristics of TB in this population remain scarce. METHODS: A single-center, retrospective descriptive study was conducted at King Chulalongkorn Memorial Hospital. Adult patients who developed TB between January 2008 and October 2018 after diagnosis of solid or hematologic malignancy were identified using ICD-10 code. Baseline, clinical characteristics, and treatment outcomes were collected. RESULTS: A total of 114 patients developed TB after diagnosis of malignancy including, 67 (58.8%) with solid tumor and 47 (41.2%) with hematologic malignancy. Lung cancer was the most common solid malignancy with TB (17.9%) followed by head and neck carcinoma (14.9%) and colorectal cancer (13.4%). For hematologic malignancies, non-Hodgkin’s lymphoma was the most common malignancy (53.2%) followed by leukemia (29.8%) and multiple myeloma (14.9%). Among patients who received immunosuppressive treatment, the mean onset of TB was 4.97 months (range 0.25 to 57 months) and 2.55 months (range 0.1 to 18 months) after treatment of solid and hematologic malignancies. Pulmonary and pleural involvement remained the most common site of infection in both groups. Mortality was highest among patients with hematologic malignancies (40.4%) while mortality in solid malignancies was 11.9%. CONCLUSION: TB in patients with solid and hematologic malignancies contained substantial morbidity and mortality. Immunosuppressive agents and chemotherapy may play an important role especially in the endemic area. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808654/ http://dx.doi.org/10.1093/ofid/ofz360.1242 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Buppanharun, Jirawat
Vanichanan, Jakapat
1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
title 1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
title_full 1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
title_fullStr 1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
title_full_unstemmed 1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
title_short 1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
title_sort 1378. clinical characteristics of tuberculosis among patients with cancer in an endemic country
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808654/
http://dx.doi.org/10.1093/ofid/ofz360.1242
work_keys_str_mv AT buppanharunjirawat 1378clinicalcharacteristicsoftuberculosisamongpatientswithcancerinanendemiccountry
AT vanichananjakapat 1378clinicalcharacteristicsoftuberculosisamongpatientswithcancerinanendemiccountry